Rapivab

Peramivir (trade name Rapivab) is an antiviral drug developed by BioCryst Pharmaceuticals for the treatment of influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. It is approved for intravenous administration.[1] In October 2009, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the use of pera... [wikipedia]